/ /

John Jesitus
John Jesitus is a medical writer based in Westminster, CO.
New therapeutic option
Long-term data for dupilumab in atopic dermatitis revealed at the American Academy of Dermatology (AAD) 75th Annual Meeting reflect safety, rapid relief of troublesome symptoms and a long-lived response in keeping with the drug’s breakthrough status, experts told Dermatology Times.
Fitting in
The approval of dupilumab (Dupixent, Sanofi Regeneron) for moderate-to-severe atopic dermatitis adds a much-needed option that may alter the broader course of atopic disease, experts told Dermatology Times.
Checkpoint inhibitors flourish
Key publications from the past year have enhanced our understanding of immunomodulatory drugs for advanced and metastatic skin cancers. Others could portend significant practice changes in areas such as sentinel lymph node (SLN) biopsy, says one dermatologist
IL-31 at center stage
A novel interleukin (IL) antagonist currently in phase 2 studies could advance the treatment of atopic dermatitis (AD), according to dermatologist.
Paradoxical reactions to biologics provide insight
Paradoxical reactions to biologic treatments can provide clues into related conditions such as granulomatous diseases, genetic polymorphisms and latent infections, says an expert.
The feminine mystique
Surgical and nonsurgical options provide effective treatment for the growing number of women seeking vaginal rejuvenation, experts say.
A new class steps forward
Phosphodiesterase (PDE) inhibitors including apremilast and crisaborole ointment may provide safer alternatives than traditional steroid-sparing agents for psoriasis and atopic dermatitis. Side effects of apremilast may include GI symptoms, weight loss and depression, and taking apremilast with anti-seizure drugs or rifampin lowers apremilast blood levels, Apremilast is being studied in inflammatory bowel disease, Behcet's disease and pediatric psoriasis, and may have a place in the treatment of hidradenitis suppurativa (HS).
TNF alfpha inhibitor safety, efficacy data grows
Long-term follow-up studies and drug registries continue to deliver reassuring data regarding the safety and efficacy of TNF inhibitors, an expert says.
TNF inhibitor treatment tactics
With a long history in dermatology and rheumatology, TNF inhibitors can not only improve psoriasis and psoriatic arthritis, but they also may reduce comorbid cardiovascular risks and work better combined with methotrexate. Low doses of cyclosporine may be effective at treating the psoriasis reaction when topicals have proven ineffective. Aggressively managing TNF-induced reactions can help patients stay on drugs that are working for other challenging diseases.
Psoriasis underdiagnosed, undertreated
In skin of color, psoriasis can be tough to spot, and it carries a broader differential diagnosis. Darker-skinned patients may not know that they can develop psoriasis, or the importance of seeking treatment early.

Poll

View Results